AU1345697A - Novel integrin receptor antagonists - Google Patents
Novel integrin receptor antagonistsInfo
- Publication number
- AU1345697A AU1345697A AU13456/97A AU1345697A AU1345697A AU 1345697 A AU1345697 A AU 1345697A AU 13456/97 A AU13456/97 A AU 13456/97A AU 1345697 A AU1345697 A AU 1345697A AU 1345697 A AU1345697 A AU 1345697A
- Authority
- AU
- Australia
- Prior art keywords
- receptor antagonists
- integrin receptor
- novel integrin
- novel
- antagonists
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US908895P | 1995-12-22 | 1995-12-22 | |
| US009088 | 1995-12-22 | ||
| US64666396A | 1996-05-08 | 1996-05-08 | |
| US646663 | 1996-05-08 | ||
| US2569996P | 1996-09-09 | 1996-09-09 | |
| US025699 | 1996-09-09 | ||
| PCT/US1996/020523 WO1997023480A1 (en) | 1995-12-22 | 1996-12-18 | Novel integrin receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU1345697A true AU1345697A (en) | 1997-07-17 |
Family
ID=27358780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU13456/97A Abandoned AU1345697A (en) | 1995-12-22 | 1996-12-18 | Novel integrin receptor antagonists |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0939757A1 (en) |
| JP (1) | JP2000501105A (en) |
| AU (1) | AU1345697A (en) |
| CA (1) | CA2240439A1 (en) |
| HR (1) | HRP960611A2 (en) |
| WO (1) | WO1997023480A1 (en) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998043962A1 (en) * | 1997-03-28 | 1998-10-08 | Du Pont Pharmaceuticals Company | Heterocyclic integrin inhibitor prodrugs |
| GB9805655D0 (en) | 1998-03-16 | 1998-05-13 | Celltech Therapeutics Ltd | Chemical compounds |
| US6521626B1 (en) | 1998-03-24 | 2003-02-18 | Celltech R&D Limited | Thiocarboxamide derivatives |
| US6524553B2 (en) | 1998-03-31 | 2003-02-25 | Bristol-Myers Squibb Pharma Company | Quinolone vitronectin receptor antagonist pharmaceuticals |
| US6537520B1 (en) | 1998-03-31 | 2003-03-25 | Bristol-Myers Squibb Pharma Company | Pharmaceuticals for the imaging of angiogenic disorders |
| US6548663B1 (en) | 1998-03-31 | 2003-04-15 | Bristol-Myers Squibb Pharma Company | Benzodiazepine vitronectin receptor antagonist pharmaceuticals |
| AU3213799A (en) * | 1998-04-01 | 1999-10-18 | Du Pont Pharmaceuticals Company | Integrin antagonists |
| CA2327673C (en) | 1998-04-09 | 2009-08-25 | Meiji Seika Kaisha, Ltd. | Aminopiperidine derivatives as integrin .alpha.v.beta.3 antagonists |
| GB9814414D0 (en) | 1998-07-03 | 1998-09-02 | Celltech Therapeutics Ltd | Chemical compounds |
| US6326379B1 (en) | 1998-09-16 | 2001-12-04 | Bristol-Myers Squibb Co. | Fused pyridine inhibitors of cGMP phosphodiesterase |
| GB9821061D0 (en) | 1998-09-28 | 1998-11-18 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9826174D0 (en) | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
| US6558649B1 (en) | 1998-12-18 | 2003-05-06 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
| PT1140203E (en) * | 1998-12-18 | 2007-08-30 | Bristol Myers Squibb Pharma Co | Vitronectin receptor antagonist pharmaceuticals |
| US6511649B1 (en) | 1998-12-18 | 2003-01-28 | Thomas D. Harris | Vitronectin receptor antagonist pharmaceuticals |
| JP2002532440A (en) | 1998-12-18 | 2002-10-02 | デュポン ファーマシューティカルズ カンパニー | Vitronectin receptor antagonist drug |
| US6569402B1 (en) | 1998-12-18 | 2003-05-27 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
| US6794518B1 (en) | 1998-12-18 | 2004-09-21 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
| BR9917080A (en) * | 1998-12-23 | 2002-03-12 | Du Pont Pharm Co | Compound, pharmaceutical composition, use of the compound and method of treatment or prevention of thromboembolic dysfunction |
| US6833373B1 (en) | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| US6518283B1 (en) | 1999-05-28 | 2003-02-11 | Celltech R&D Limited | Squaric acid derivatives |
| EP1198231A1 (en) | 1999-07-21 | 2002-04-24 | American Home Products Corporation | Bicyclic antagonists selective for the(alpha)v(beta)3 integrin |
| AU6316900A (en) | 1999-08-05 | 2001-03-05 | Meiji Seika Kaisha Ltd. | Omega-amino-alpha-hydroxycarboxylic acid derivatives having integrin alphavbeta3antagonism |
| CA2380817A1 (en) * | 1999-08-13 | 2001-02-22 | Biogen, Inc. | Cell adhesion inhibitors |
| US6534513B1 (en) | 1999-09-29 | 2003-03-18 | Celltech R&D Limited | Phenylalkanoic acid derivatives |
| US6455539B2 (en) | 1999-12-23 | 2002-09-24 | Celltech R&D Limited | Squaric acid derivates |
| US6436915B1 (en) * | 2000-04-07 | 2002-08-20 | Kinetek Pharmaceuticals, Inc. | Pyrazole compounds |
| JP2003531141A (en) | 2000-04-17 | 2003-10-21 | セルテック アール アンド ディ リミテッド | Enamine derivatives |
| US6545013B2 (en) | 2000-05-30 | 2003-04-08 | Celltech R&D Limited | 2,7-naphthyridine derivatives |
| US6403608B1 (en) | 2000-05-30 | 2002-06-11 | Celltech R&D, Ltd. | 3-Substituted isoquinolin-1-yl derivatives |
| AU7002501A (en) * | 2000-06-21 | 2002-01-02 | Du Pont Pharm Co | Vitronectin receptor antagonist pharmaceuticals for use in combination therapy |
| WO2002004426A1 (en) | 2000-07-07 | 2002-01-17 | Celltech R & D Limited | Squaric acid derivatives containing a bicyclic heteroaromatic ring as integrin antagonists |
| WO2002010136A1 (en) | 2000-08-02 | 2002-02-07 | Celltech R & D Limited | 3-substituted isoquinolin-1-yl derivatives |
| EP1380576B1 (en) | 2001-04-16 | 2009-11-25 | Eisai R&D Management Co., Ltd. | 1h-indazole compounds inhibiting jnk |
| AU2004293443A1 (en) | 2003-11-19 | 2005-06-09 | Signal Pharmaceuticals, Llc. | Indazole Compounds and methods of use thereof as protein kinase inhibitors |
| US20070155738A1 (en) | 2005-05-20 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
| WO2007013964A1 (en) | 2005-07-22 | 2007-02-01 | Sunesis Pharmaceuticals, Inc. | Pyrazolo pyrimidines useful as aurora kinase inhibitors |
| WO2007058626A1 (en) * | 2005-11-16 | 2007-05-24 | S*Bio Pte Ltd | Indazole compounds |
| AU2007206016A1 (en) | 2006-01-13 | 2007-07-26 | Wyeth | Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors |
| TWI444379B (en) | 2007-06-29 | 2014-07-11 | Sunesis Pharmaceuticals Inc | Compounds useful as raf kinase inhibitors |
| EP2167497A2 (en) | 2007-06-29 | 2010-03-31 | Sunesis Pharmaceuticals, Inc. | Heterocyclic compounds useful as raf kinase inhibitors |
| JP5216912B2 (en) | 2008-04-29 | 2013-06-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Indazole compounds as CCR1 receptor antagonists |
| JP5411927B2 (en) | 2008-05-06 | 2014-02-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Pyrazole compounds as CCR1 antagonists |
| WO2009148290A2 (en) * | 2008-06-05 | 2009-12-10 | Sk Holdings Co., Ltd. | 3-substituted propanamine compounds |
| US8101642B2 (en) | 2008-06-05 | 2012-01-24 | Sk Biopharmaceuticals Co., Ltd. | 3-substituted propanamine compounds |
| PE20110854A1 (en) | 2008-09-26 | 2011-12-23 | Boehringer Ingelheim Int | DERIVATIVES OF 1-PHENYL-1H-PYRAZOLO [3,4-c] PYRIDINE-4-CARBONYLAMINE AS ANTAGONISTS OF CCR1 RECEPTORS |
| AU2010229144B2 (en) * | 2009-03-23 | 2012-07-12 | Merck Sharp & Dohme Corp. | P2X3, receptor antagonists for treatment of pain |
| CN102666526A (en) | 2009-10-21 | 2012-09-12 | 贝林格尔.英格海姆国际有限公司 | Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists |
| WO2011056440A1 (en) | 2009-10-27 | 2011-05-12 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds as ccr1 receptor antagonists |
| WO2011137109A1 (en) | 2010-04-30 | 2011-11-03 | Boehringer Ingelheim International Gmbh | Azaindazole amide compounds as ccr1 receptor antagonists |
| WO2011156889A1 (en) * | 2010-06-14 | 2011-12-22 | Trt Pharma Inc. | Novel modulators of nrf2 and uses thereof |
| US8546442B2 (en) | 2010-12-23 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Pyrazolopiperidine compounds as CCR1 receptor antagonists |
| WO2013096496A2 (en) | 2011-12-21 | 2013-06-27 | Allergan, Inc. | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response |
| KR20130077390A (en) * | 2011-12-29 | 2013-07-09 | 제이더블유중외제약 주식회사 | 6-amino-3-carboxamidoindazole derivatives as protein kinase inhibitors |
| WO2016000615A1 (en) * | 2014-07-02 | 2016-01-07 | Sunshine Lake Pharma Co., Ltd. | Heteroaryl compounds and pharmaceutical applications thereof |
| EA201991123A1 (en) * | 2016-11-08 | 2019-11-29 | INDAZOLE DERIVATIVES AS ANTEGRIN ANTAGONISTS αV | |
| SG11202104081XA (en) * | 2018-10-25 | 2021-05-28 | Merck Patent Gmbh | 5-azaindazole derivatives as adenosine receptor antagonists |
| CN112694474B (en) * | 2019-10-23 | 2022-03-18 | 四川大学 | Indazole derivative and preparation method and application thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2155123A1 (en) * | 1993-02-22 | 1994-09-01 | David Alan Claremon | Fibrinogen receptor antagonists |
| CA2134192A1 (en) * | 1993-11-12 | 1995-05-13 | Michael L. Denney | 5, 6-bicyclic glycoprotein iib/iiia antagonists |
| PT730590E (en) * | 1993-11-24 | 2001-05-31 | Du Pont Pharm Co | ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS ANTAGONISTS OF FIBRINOGENIC RECIPIENTS |
-
1996
- 1996-12-18 WO PCT/US1996/020523 patent/WO1997023480A1/en not_active Application Discontinuation
- 1996-12-18 CA CA002240439A patent/CA2240439A1/en not_active Abandoned
- 1996-12-18 AU AU13456/97A patent/AU1345697A/en not_active Abandoned
- 1996-12-18 EP EP96944984A patent/EP0939757A1/en not_active Withdrawn
- 1996-12-18 JP JP9523845A patent/JP2000501105A/en active Pending
- 1996-12-20 HR HR60/025,699A patent/HRP960611A2/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0939757A1 (en) | 1999-09-08 |
| HRP960611A2 (en) | 1998-04-30 |
| CA2240439A1 (en) | 1997-07-03 |
| WO1997023480A1 (en) | 1997-07-03 |
| JP2000501105A (en) | 2000-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU1345697A (en) | Novel integrin receptor antagonists | |
| AU7692996A (en) | Receptor antagonists | |
| AU4803996A (en) | Endothelin receptor antagonists | |
| AU8689798A (en) | Integrin receptor antagonists | |
| AU4746297A (en) | Vitronectin receptor antagonists | |
| HU9601529D0 (en) | Pyrimidinedion-, pyrimidinetrion-, triazinedion-, tetrahydro-quinazolinedion- derivatives as alpha-adrenerg receptor antagonists | |
| AU5440996A (en) | 2-acylaminopropanamides as tachykinin receptor antagonists | |
| AU2143295A (en) | Neurokinin receptor antagonists | |
| AU1765695A (en) | Non-peptidyl tachykinin receptor antagonists | |
| AU7694496A (en) | Endothelin receptor antagonists | |
| EP0810994A4 (en) | Fibrinogen receptor antagonists | |
| EP0866705A4 (en) | Fibrinogen receptor antagonists | |
| AU5196996A (en) | Adhesion receptor antagonists | |
| EP0880511A4 (en) | Integrin receptor antagonists | |
| AU1230795A (en) | Adhesion receptor antagonists | |
| AU6856796A (en) | Des-arg9-bk antagonists | |
| AU6679296A (en) | Hepadnavirus receptor | |
| AU6748196A (en) | Receptor | |
| AU3661895A (en) | Adhesion receptor antagonists | |
| AU6646396A (en) | Endothelin receptor antagonists | |
| AU6060796A (en) | Endothelin receptor antagonists | |
| EP0854721A4 (en) | Endothelin receptor antagonists | |
| AU6079296A (en) | Endothelin receptor antagonists | |
| AU4446296A (en) | Adhesion receptor antagonists | |
| AUPO938697A0 (en) | Novel receptor |